Dermatology Excimer Laser Market Research and Forecasts 2023-2024 & 2024-2034: Growing Trend Toward Specialized Centers Focused on Advanced Dermatological Treatments
January 29, 2025 11:05 ET
|
Research and Markets
Dublin, Jan. 29, 2025 (GLOBE NEWSWIRE) -- The "Dermatology Excimer Laser Market by Product, by Application, by End-User, and By Region" report has been added to ResearchAndMarkets.com's...
Arcutis Submits ZORYVE® (roflumilast) Cream 0.05% Supplemental New Drug Application to the FDA for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis
December 16, 2024 08:00 ET
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced the submission of an sNDA to the FDA for ZORYVE (roflumilast) cream 0.05% for children aged 2 to 5 for mild to moderate AD.
Arcutis’ ZORYVE® (roflumilast) Awarded Best Eczema Treatment by Glamour
November 13, 2024 08:00 ET
|
Arcutis Biotherapeutics, Inc.
ZORYVE cream 0.15% is the first once-daily, Food and Drug Administration (FDA)-approved topical treatment for mild to moderate atopic dermatitisZORYVE, a next-generation topical phosphodiesterase-4...
Dermatology Treatment and Care Research Report 2024-2030 with Analyst Recommendations - Tapping into the Demand for Tailored Solutions / Focus on Expansion in Emerging Markets
October 29, 2024 05:01 ET
|
Research and Markets
Dublin, Oct. 29, 2024 (GLOBE NEWSWIRE) -- The "Global Dermatology Treatment and Care Market (2024 Edition): Analysis By Treatment Type (Skin Disease and Care, Hair Disease and Care), By Route of...
Arcutis Presents Positive Patient-Reported Outcome Data for ZORYVE® (Roflumilast) Cream 0.15% in Atopic Dermatitis at American College of Allergy, Asthma and Immunology 2024 Annual Scientific Meeting
October 24, 2024 08:00 ET
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced new patient-reported outcome data demonstrating that ZORYVE cream 0.15% improved the impact of AD on patients and families.
New Data Shows ZORYVE® (Roflumilast) Cream 0.15% Provided Consistent Improvement of Atopic Dermatitis in Individuals With Diverse Skin Types
September 25, 2024 01:00 ET
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced new pooled subgroup analysis results from the Phase 3 INTEGUMENT-1 and -2 trials.
The Highly Anticipated FDA Approvals of Galderma’s Nemolizumab and Eli Lilly’s Lebrikizumab are Expected to Shift Dermatologists’ Perceptions of the Atopic Dermatitis Market
September 09, 2024 10:20 ET
|
Spherix Global Insights
EXTON, PA, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Since its 2017 debut as the first advanced systemic treatment for atopic dermatitis (AD), Sanofi/Regeneron’s Dupixent has dominated the US market....
U.S. Dermatology Imaging Devices Market Report 2024-2030: Digital Photographic Imaging, OCT, Dermatoscope, Skin Cancers, Inflammatory Dermatoses Size, Share & Trends Analysis
September 09, 2024 07:34 ET
|
Research and Markets
Dublin, Sept. 09, 2024 (GLOBE NEWSWIRE) -- The "U.S. Dermatology Imaging Devices Market Size, Share & Trends Analysis Report By Modality (Digital Photographic Imaging, OCT, Dermatoscope), By...
Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.05% Show Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis
August 28, 2024 08:00 ET
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced results from the INTEGUMENT-OLE long-term open-label study of once-daily roflumilast cream 0.05%.
Arcutis Launches ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis
July 29, 2024 07:30 ET
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced the commercial launch of ZORYVE® (roflumilast) cream 0.15% for the treatment of mild to moderate atopic dermatitis.